Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects a systematic review and meta-analysis of randomized clinical trials

JAMA Psychiatry

Volumn 71, Issue 12, 2014, Pages 1381-1391

  Köhler, Ole ^a   E Benros, Michael ^b   Nordentoft, Merete ^b   Farkouh, Michael E ^c,d   Iyengar, Rupa L ^c,e   Mors, Ole ^a   Krogh, Jesper ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST GEORGE S UNIVERSITY SCHOOL OF MEDICINE   (Grenada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE INHIBITOR; CYTOKINE RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84915812914     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.1611     Document Type: Review

References (55)

1. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56
2. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: ameta-analysis. Psychosom Med. 2009;71(2):171-186
3. Dowlati Y, Herrmann N, SwardfagerW, et al. Ameta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457
4. Benros ME,Waltoft BL, NordentoftM, et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry. 2013;70(8):812-820
5. Friebe A, HornM, Schmidt F, et al. Dose-dependent development of depressive symptoms during adjuvant interferon-α treatment of patients with malignant melanoma. Psychosomatics. 2010;51(6):466-473
6. Mller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680-684
7. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367 (9504):29-35
8. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A. 2011;108(22): 9262-9267
9. Gallagher PJ, Castro V, Fava M, et al. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry. 2012; 169(10):1065-1072
10. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008;65(7):795-803
11. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrentmyocardial infarction in patients with priormyocardial infarction: a nationwide cohort study. Circulation. 2011;123 (20):2226-2235
12. Toussi SS, Pan N,Walters HM,Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-alpha inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57(9):1318-1330
13. Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: ameta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;48: 79-85
14. Iyengar RL, Gandhi S, Aneja A, et al. NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med. 2013;126(11):e11-e18. doi:10.1016/j.amjmed.2013.02.037
15. Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163(6):493-501
16. Manning JS, JacksonWC. Depression, pain, and comorbid medical conditions. J Clin Psychiatry. 2013;74(2):e03. doi:10.4088/JCP.12049vs3c
17. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley & Sons; 2008:187-235
18. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995; 273(5):408-412
19. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported inmeta-analyses? Lancet. 1998;352(9128):609-613
20. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135(11):982-989
21. Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? empirical study. Health Technol Assess. 2003;7(1):1-76
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ. 2003;327(7414):557-560
23. Nordic Cochrane Centre. RevMan, Version 5.2. Copenhagen, Denmark: Nordic Cochrane Centre, Cochrane Collaboration; 2008
24. Raison C, Rutherford RE,Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2012;26(suppl 1):S49. doi:10.1016/j.bbi.2012.07.200.W
25. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141 (2-3):308-314
26. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607-611
27. Hashemian F, MajdM, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bul. 2011;21:S183-S184
28. Fields C, Drye L, Vaidya V, Lyketsos C; ADAPT Research Group. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. Am J Geriatr Psychiatry. 2012;20 (6):505-513
29. Menter A, Augustin M, Signorovitch J, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J AmAcad Dermatol. 2010;62(5):812-818
30. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J AmAcad Dermatol. 2010;63(3):457-465
31. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of themisleading funnel plot. BMJ. 2006;333(7568):597-600
32. Uher R, Carver S, Power RA, et al. Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med. 2012;42(10):2027-2035
33. Collantes-Estevez E, Fernandez-Perez C. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin. 2003;19(5):402-410
34. Johansson D, Falk A, Marcus MM, Svensson TH. Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):143-148
35. Ertenli I, Ozer S, Kiraz S, et al. Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int. 2012;32(2):323-330
36. Karson A, Demirtas T, Bayramgurler D, Balci F, Utkan T. Chronic administration of infliximab (TNF-α inhibitor) decreases depression and anxiety-like behaviour in rat model of chronicmild stress. Basic Clin Pharmacol Toxicol. 2013;112(5): 335-340
37. Persoons P, Vermeire S, Demyttenaere K, et al. The impact of major depressive disorder on the short-and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther. 2005;22(2):101-110
38. Solomon DH, Avorn J, Strmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006;54(5): 1378-1389
39. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol. 2006;21(4):227-231
40. O'Neil A, Sanna L, Redlich C, et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med. 2012;10:154. doi:10.1186/1741-7015-10-154
41. Miyaoka T, Wake R, FuruyaM, et al.Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(2): 222-226
42. Toms-Camardiel M, Rite I, Herrera AJ, et al. Minocycline reduces the lipopolysaccharideinduced inflammatory reaction, peroxynitritemediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis. 2004;16(1): 190-201
43. Fond G, Hamdani N, Kapczinski F, et al. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand. 2014;129(3):163-179
44. BerkM, Dean O, Drexhage H, et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 2013;11:74. doi:10.1186/1741-7015-11-74
45. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood.AmJ Clin Nutr. 2010;91(3):757-770
46. Sepanjnia K, Modabbernia A, AshrafiM, ModabberniaMJ, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37(9):2093-2100
47. Kashani L, Omidvar T, Farazmand B, et al. Does pioglitazone improve depression through insulin-sensitization? results of a randomized double-blindmetformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 2013;38 (6):767-776
48. Abolfazli R, Hosseini M, Ghanizadeh A, et al. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil vs fluoxetine plus placebo in the treatment of major depression. Depress Anxiety. 2011;28(4):297-302
49. Otte C, Hinkelmann K, Moritz S, et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res. 2010;44(6):339-346
50. Arana GW, Santos AB, LaraiaMT, et al. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry. 1995;152(2):265-267
51. DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2000;157(8):1334-1337
52. Wium-Andersen MK, Orsted DD, Nordestgaard BG. Elevated C-reactive protein, depression, somatic diseases, and all-cause mortality: a mendelian randomization study. Biol Psychiatry. 2014;76(3):249-257
53. Sommer IE, deWitte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? a meta-analysis. J Clin Psychiatry. 2012;73(4):414-419
54. Nitta M, Kishimoto T, Mller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: ameta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013; 39(6):1230-1241
55. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87-94